The Department of Defense Pharmacy & Therapeutics (DoD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).
DoD P&T Committee Meeting Schedule
DoD P&T Meeting Minutes
November 16-17, 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Anticoagulants - Oral Anticoagulants
- Antilipidemics-1 - PCSK9s
|
Spiriva Respimat
|
Bevespi Aeroshere, Byvalson, Emend, Gonitro, Invokamet XR, Otovel, Qbrelis, Relistor, Taytulla, Vonvendi, Xiidra, Yosprala, Zinbryta, Zurampic |
August 10-11, 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Acne Agents - Topical and Roseacea Agents
- Migraine Agents - Triptans
- Alcohol Deterrents - Narcotic Antagonists
|
N/A |
Afstyla, Briviact, Cabometyx, Aczone, Descovy, Epclusa, Ferriprox, Jentadueto XR, Nuplazid, Ocaliva, Orfadin, Sernivo, Onzetra Xsail, Zembrance SymTouch, Tolak, Ultravate, Venclexta, Xtampza ER |
May 11-12, 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Oral Contraceptives - Emergency Contraceptives
- Anticonvulsants
- Antipsychotic Agents - Atypical
|
Entresto, Viberzi
Zecuity - Solicitation Cancelled
|
Adzenys XR-ODT, Belbuca, Enstilar, Idelvion, Kovaltry, Odefsey, Quillichew ER, Taltz, Vraylar, Xeljanx XR, Xuriden, Zepatier
|
February 2016
| Class Review |
Designated Newly Approved Drugs |
FDA Innovator Drugs |
- Oral Contraceptives
- Antifungal Agents - Topical Laquers
- Opthalmic Anti-Inflammatory/ Immunomodulatory Agents - Ophthalmic Immunomodulatory Agents
|
Tivorbex, Pazeo, Afrezza, Striverdi Respimat
Rexulti, Entresto -Solicitation cancelled
|
Adynovate, Alecensa, Coagadex, Cotellic, Durlaza, Dyanavel XR, Genvoya, Narcan nasal, Ninlaro, Seebri Neohaler, Strensiq, Tagrisso, Tresiba, Uptravi, Utibron Neohaler, Varubi, Veltassa, Vivlodex
|
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.